- Oops!Something went wrong.Please try again later.
New York, New York--(Newsfile Corp. - August 17, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Rigel Pharmaceuticals, Inc. ("Rigel" or the "Company") (NASDAQ: RIGL). Such investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, ext. 7980.
The investigation concerns whether Rigel and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On August 13, 2021, Rigel issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) has informed the Company that clinical data submitted in late-May from a 59-patient NIH/NHLBI-sponsored Phase 2 trial of fostamatinib to treat hospitalized patients suffering from COVID-19 are insufficient for an emergency use authorization (EUA) at this time."
On this news, Rigel's stock price fell $0.41 per share, or 9.93%, to close at $3.72 per share on August 13, 2021.
The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.
Robert S. Willoughby
888-476-6529 ext. 7980
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/93484